Skip to content
OpenCapital
Get started

Palvella Therapeutics PVLA Q3 2025 earnings

Reported November 11, 2025 · Before market open

EPS-$1.03Miss by $0.18
EPS estimate-$0.85

Next report

Aug 13, 2026 (In 2 weeks)
EPS estimate-$1.16

Financials

Q3 2025

Income statement

See full
Operating income-$10.2M-101%
Net income-$11.3M-67.5%
EPS (diluted)-$1.03+73.9%

Balance sheet

See full
Cash & equivalents$63.6M+228%
Total equity$38.7M+144%
Total assets$66.9M+226%

Cash flow

See full
Operating cash flow-$7.9M-187%

Versus estimates

Diluted EPS

Q1 2026-$1.20Miss by $0.30Q4 2025-$1.08Miss by $0.17
Q3 2025-$1.03Miss by $0.18
Q2 2025-$0.86Miss by $0.08Q1 2025-$0.74Beat by $2.66Q4 2024$4.00Beat by $4.39

Ask the moment Palvella Therapeutics reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Palvella Therapeutics report Q3 2025 earnings?
Palvella Therapeutics (PVLA) reported Q3 2025 earnings on November 11, 2025 before market open.
What were Palvella Therapeutics's Q3 2025 revenue and EPS?
Palvella Therapeutics reported eps of $-1.03 for Q3 2025.
Did Palvella Therapeutics beat estimates in Q3 2025?
EPS missed the consensus estimate of $-0.85 by $0.18.
How did Palvella Therapeutics's Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, eps grew 53.0% from $-2.19.
Where can I find Palvella Therapeutics's Q3 2025 SEC filings?
You can read the 8-K earnings release (0001193125-25-274378) and the 10-Q periodic report (0001193125-25-276119) directly on SEC EDGAR. The filing index links above go to sec.gov.